Early detection and innovative biologic treatment can prevent hospitalizations, improve quality of life, and extend the ...

Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026. Upstream Bio, Inc. has initiated a global Phase 2 clinical ...

Milan, Italy: For the first time, researchers have shown it is possible to repair damaged lung tissue in patients with chronic obstructive pulmonary disease (COPD) using the patients’ own lung cells.

She told us her life changed when she sought treatment at Christ Hospital and met Dr. Duane Allen, a pulmonary and critical ...

Jul. 1—MORGANTOWN — A new treatment for emphysema is coming to West Virginia. The Zephyr Valve, a treatment classified a medical breakthrough by the Food and Drug Administration, will be offered by ...

Moderate COPD may mean that physical activity is more difficult, and you may cough up mucus more regularly. People with moderate COPD can take steps to improve their life expectancy by preventing ...

There’s no cure for chronic obstructive pulmonary disease (COPD). But there are things you can do to stay active, breathe easier, and live longer -- even if your condition is more advanced. Ask your ...

Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...

WHITTIER, Calif., Nov. 19, 2025 /PRNewswire/ -- PIH Health Whittier Hospital is now offering the Zephyr (R) Endobronchial Valve procedure, a breakthrough minimally invasive treatment option for ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication of long ...

Both agents are long-acting muscarinic antagonists. The primary endpoint of the study was the change from baseline in trough FEV 1 at day 85. Findings showed no statistically significant difference ...